A Multicenter, Randomized, Double-Blind, Placebo-Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis

Authors
Category Primary study
Registry of TrialsOverview of Medical Research in the Netherlands
Year 2018
This article has no abstract
Epistemonikos ID: 32822ace900fc1ffac00507b24b9a1425e261235
First added on: Apr 11, 2025